Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Transcripts
    • AGM Invitations
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team

Enorama Pharma

0.50 SEK

-19.94 %

Less than 1K followers

ERMA

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Valuation
Income statement
Quarter data

Income statement

Financial statements, revenue, EBIT, valuation metrics, and quarterly estimates for Enorama Pharma

201920202021202220232024
Revenue7.62.111.06.91.415.8
growth-%-71.8 %414.3 %-37.9 %-80.1 %1,059.6 %
EBITDA-22.7-22.7-25.6-36.0-38.6-27.1
EBIT-22.9-23.0-26.9-39.5-42.1-47.5
Profit before taxes-23.8-23.5-27.7-40.1-44.6-43.8
Net income-23.8-23.5-27.7-40.1-44.6-43.8
EPS-3.65-3.28-2.98-3.54-0.90-0.72
Dividend0.000.000.000.000.000.00
Dividend ratio-0.0 %-0.0 %-0.0 %-0.0 %-0.0 %-0.0 %

Profitability and return on capital

201920202021202220232024
EBITDA-%-298.6 %-1,057.3 %-231.6 %-525.3 %-2,836.8 %-171.9 %
EBIT-%-300.6 %-1,072.3 %-244.1 %-576.9 %-3,097.8 %-301.3 %
ROE-331.5 %-1,320.0 %-129.9 %-119.7 %-228.3 %-561.7 %
ROI-55.9 %-57.3 %-54.5 %-79.1 %-129.7 %-275.7 %
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.